About this trial
Mild cognitive impairment (MCI) is often considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease (AD). Patients with MCI have subjective memory complaints corroborated by standard neuropsychological tests but remain functionally autonomous. One of the first brain regions to show AD pathology is the hippocampus (HPC). Reduction in HPC volume is a strong predictor of AD dementia. Therefore, improvement or restoration of HPC structure and function is thus an attractive target for improvement in memory and AD prevention strategies. In the current study, the investigators propose to examine the effects of a 3-month long spatial memory program on spatial memory and the hippocampus in patients diagnosed with MCI. Neuropsychological tests are also administered before and after the training to assess the effects of the intervention on cognition. In our previous research, the investigators have shown that spatial memory intervention program (SMIP) improves cognition and hippocampal based spatial memory compared to controls.
Eligibility criteria
Qualifiers
Age 55 years and above.
Primary language is English or French.
Individuals having received a diagnosis of Mild Cognitive Impairment (MCI).
Disqualifiers
Current medications for sleep problems, or use of medications that affect sleep.
Use of antidepressant and anti-anxiety medication for less than 3 months prior to study entry.
Use of analgesics with codeine (or other opioids).
Use of antipsychotic medication (past or current).
Trial design
Treatments tested in this trial
- SMIP
- No intervention
Treatment groups
Sponsors and collaborators
Douglas Mental Health University Institute
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator